J INTS BIO Unveils Promising Results for JIN-A02, a Fourth-Generation EGFR Inhibitor J INTS BIO has revealed groundbreaking clinical research on JIN-A02, a fourth-generation EGFR inhibitor, offering new hope for patients with lung cancer.

J INTS BIO Unveils Promising Results for JIN-A02, a Fourth-Generation EGFR Inhibitor #South_Korea #Seoul #J_INTS_BIO #EGFR_Inhibitor #JIN-A02

Eilean Therapeutics Unveils Groundbreaking Pan-EGFR Inhibitor for NSCLC Treatment at Major Cancer Conference Eilean Therapeutics showcases their innovative pan-EGFR inhibitor, ZE77-0273, at the AACR-NCI-EORTC conference, highlighting its promise in non-small cell lung cancer treatment.

Eilean Therapeutics Unveils Groundbreaking Pan-EGFR Inhibitor for NSCLC Treatment at Major Cancer Conference #United_States #Dover #EGFR_Inhibitor #Eilean_Therapeutics #ZE77-0273

Hoth Therapeutics Unveils Promising Results for HT-001 Targeting EGFR Inhibitor-Associated Skin Eruptions Hoth Therapeutics announces impressive findings for HT-001, a potential breakthrough in treating skin eruptions from EGFR inhibitors, to be revealed at AAD 2025.

Hoth Therapeutics Unveils Promising Results for HT-001 Targeting EGFR Inhibitor-Associated Skin Eruptions #USA #New_York #Hoth_Therapeutics #HT-001 #EGFR_Inhibitor